Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review.

Pharmaceut Med · 2024 · PMC11625068 · PMID 39612120

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a statistical trendno p-value reported

Patients who refused to switch also showed a statistical trend towards older age, longer disease duration and a long history of originator (etanercept) use.

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.